Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report

Tyrosine kinase inhibitors (TKIs) represent the standard treatment for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. The duration of the response is, however, limited in time owing to the development of resistance mechanisms to both fir...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Case Rep Oncol
Autors principals: Blasi, Miriam, Kazdal, Daniel, Thomas, Michael, Christopoulos, Petros, Kriegsmann, Mark, Brandt, Regine, Volckmar, Anna-Lena, Kirchner, Martina, Heußel, Claus Peter, Stenzinger, Albrecht, Kuon, Jonas
Format: Artigo
Idioma:Inglês
Publicat: S. Karger AG 2021
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8077408/
https://ncbi.nlm.nih.gov/pubmed/33976623
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000513904
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars